Epcoritamab Combination Hits Primary Goal in Lymphoma Phase 3 Trial

The experimental regimen, pairing epcoritamab with lenalidomide, outperformed the current standard of care—a combination of rituximab, gemcitabine, and oxaliplatin. By demonstrating a statistically significant improvement in progression-free survival, the companies have cleared a major hurdle in proving the efficacy of this treatment for an aggressive cancer that remains notoriously difficult to manage.

AbbVie and Genmab now intend to initiate discussions with global regulatory authorities to determine the path toward approval. While the full scope of the clinical data remains under wraps, the firms plan to present their findings at an upcoming medical conference, providing the oncology community with a clearer look at how this dual-therapy approach could reshape treatment protocols for B-cell malignancies.